Analysts expect Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) to announce ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aevi Genomic Medicine’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.18). Aevi Genomic Medicine posted earnings of ($0.22) per share in the same quarter last year, which suggests a positive year over year growth rate of 22.7%. The firm is expected to issue its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.85). For the next financial year, analysts expect that the company will report earnings of ($0.77) per share, with EPS estimates ranging from ($0.82) to ($0.71). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.01). During the same quarter in the prior year, the business posted ($0.29) EPS.
Separately, Jefferies Group reiterated a “hold” rating and issued a $1.50 price target on shares of Aevi Genomic Medicine in a report on Thursday, September 28th.
Aevi Genomic Medicine (GNMX) opened at $1.30 on Friday. The firm has a market cap of $76.83, a price-to-earnings ratio of -1.35 and a beta of 0.40. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.18.
In other Aevi Genomic Medicine news, CEO Michael F. Cola bought 119,047 shares of Aevi Genomic Medicine stock in a transaction that occurred on Tuesday, October 17th. The shares were acquired at an average price of $1.26 per share, for a total transaction of $149,999.22. Following the acquisition, the chief executive officer now owns 218,483 shares of the company’s stock, valued at approximately $275,288.58. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Garry Arthur Neil bought 75,000 shares of Aevi Genomic Medicine stock in a transaction that occurred on Tuesday, October 17th. The shares were acquired at an average price of $1.26 per share, for a total transaction of $94,500.00. Following the acquisition, the insider now directly owns 114,774 shares in the company, valued at approximately $144,615.24. The disclosure for this purchase can be found here. Insiders have purchased a total of 615,079 shares of company stock worth $775,000 in the last 90 days. Company insiders own 15.20% of the company’s stock.
An institutional investor recently raised its position in Aevi Genomic Medicine stock. Wells Fargo & Company MN lifted its holdings in shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by 433.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,662 shares of the biotechnology company’s stock after acquiring an additional 106,178 shares during the quarter. Wells Fargo & Company MN owned about 0.35% of Aevi Genomic Medicine worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 16.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://transcriptdaily.com/2018/01/13/analysts-anticipate-aevi-genomic-medicine-inc-gnmx-will-post-earnings-of-0-17-per-share.html.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.